ADULT AIDS CLINICAL RESEARCH

梅哈里医学院和范德比尔特的医学院 大学联合建议设立艾滋病临床试验单位， 田纳西州的纳什维尔。 此应用程序的主要目标是 成功地在艾滋病毒感染者中进行临床试验;提高 在这些试验中纳入代表性不足的人群;改善 为美国中南部地区的人们提供实验性疗法， 国家;并调查的差异和独特的方面， 艾滋病在这一地区的传播。 这项合作努力是 由于以下原因，它是可行的：1）田纳西州中部和中部- 南方的艾滋病毒感染率正在迅速上升。 这 在ACTG试验中基本上没有代表性，也无法获得 因此代表了大量潜在的临床试验 参与者 2)梅哈里医学院，凭借其招生能力， 有效地和以文化上敏感的方式， 社区，可以为整个ACTG做出独特的贡献。 第三章 范德比尔特大学在临床研究方面拥有悠久的历史， 在艾滋病毒临床试验的经验将是一个亚单位的Meharry ACTU并在开发、实施和开展 ACTG协议。 4)Meharry是目前唯一一家运营的CRC 在一个少数民族健康机构。 综合临床研究中心 （GCRC）在范德比尔特是最大的和最成功的一个在 国家 因此，这一提议为双方提供了一个理想的机会， CRC将在临床试验中进行合作。

The medical faculties at Meharry Medical College and Vanderbilt University jointly propose an AIDS Clinical Trials Unit to be located in Nashville, Tennessee. The major goals of this application are to successfully perform clinical trials in HIV-infected persons; to improve inclusion of underrepresented populations in these trials; to improve access to experimental therapies for people in the mid-South region of the country; and to investigate the differences and unique aspects of HIV-infection in this geographic area. This collaborative effort is feasible for the following reasons: 1) Middle Tennessee and the mid- South are experiencing a rapid increase in HIV infection. This population has essentially no representation in nor access to ACTG trials at present thus representing a large pool of potential clinical trial participants. 2) Meharry Medical College, with its ability to recruit effectively and in a culturally sensitive manner in the minority community, can make a unique contribution to the ACTG as a whole. 3) Vanderbilt University with its long track record in clinical research and experience in clinical trials in HIV will be a subunit of the Meharry ACTU and lend expertise in the development, implementation, and conduct of the ACTG protocols. 4) Meharry has the only CRC currently operating in a minority health institution. The General Clinical Research Center (GCRC) at Vanderbilt is the largest and one of the most successful in the country. this proposal thus provides an ideal opportunity for the two CRC's to collaborate in clinical trials.